Company Overview of Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. operates as a biotechnology company that engages in the discovery and development of ‘orally stable peptides’ against validated targets and diseases that are being addressed by ‘injectable biologics’. The company focuses on developing oral peptides for inflammatory bowel diseases (IBD), irritable bowel syndrome, and other gastro-intestinal disorders. Its development portfolio includes a4ß7 integrin specific ‘oral peptide’ antagonist for the treatment of IBD; IL-6 peptide antagonist, which is used in the treatment of various diseases, such as IBD, psoriasis, and rheumatoid arthritis; Hepcidin, a natural peptide hormone that regulates iron homeostasis and its def...
521 Cottonwood Drive
Milpitas, CA 95035-7404
Founded in 2001
Key Executives for Protagonist Therapeutics, Inc.
Founder and Vice President of Technology & Alliances
Senior Director of Preclinical Development
Compensation as of Fiscal Year 2014.
Protagonist Therapeutics, Inc. Key Developments
Protagonist Therapeutics, Inc. Presents at The 21st Annual Future Leaders in the Biotech Industry Conference, Mar-28-2014 03:00 PM
Feb 11 14
Protagonist Therapeutics, Inc. Presents at The 21st Annual Future Leaders in the Biotech Industry Conference, Mar-28-2014 03:00 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States.
Protagonist Therapeutics, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 08:00 AM
Aug 9 13
Protagonist Therapeutics, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 08:00 AM. Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.
Protagonist Therapeutics, Inc. Appoints David Y. Liu, Ph.D. as Chief Scientific Officer
May 30 13
Protagonist Therapeutics, Inc. announced the appointment of David Y. Liu, Ph.D. as Chief Scientific Officer. Dr. Liu is a former Vice President of Research and a Corporate Officer at FibroGen Inc. with deep rooted knowledge and expertise in the fields of inflammation and fibrosis. David Y. Liu was most recently Chief Operating Officer and co-founder of Trenovus, Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|